AbCellera Biologics Inc. (NASDAQ:ABCL) concluded the trading at $50.9 on Thursday, Jan 21, with a rise of 5.6% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $48.2 and 5Y monthly beta was reading 0 with its price kept floating in the range of $48.10 and $51.49 on the day. Company’s P/E ratio for the trailing 12 months is 2827.78. Considering stock’s 52-week price range provides that ABCL hit a high price of $71.91 and saw its price falling to a low level of $36.27 during that period. Over a period of past 1-month, stock came adding 3.41% in its value.
According to ratings assigned by 5 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending AbCellera Biologics Inc. (ABCL) as a Hold, while 5 are in view that stock is a Buy. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the ABCL stock which is currently positioned at 0. It further provides that stock’s current price level is 20.62% away from its 20-day simple moving average and is 15.56% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 0 while volatility remained at 8.11% over the past week which changes to 8.91% when measuring it over the past month. Beta is valued at 0, while measure of average true range or ATR is currently at 4.53. In predicting price targets of as low as $45 and as high as $59, analysts are in agreement on assigning the stock over the next 12 months average price target of $51.4. Stock’s current price level is -11.59% above from estimated low price target while it is 15.91% below the estimated high; and even if the ABCL’s share succeeded to reach the median price of $52, then the outlook of +2.16% could come to the excitement of the investors.
In comparing AbCellera Biologics Inc. (ABCL)’s stock with other industry players reveals that stock’s current price change of +5.6% and that of 0% over the past 12 months is in better position with that of Bristol-Myers Squibb Company (BMY) which saw its stock price fell by -3.12% in the last trading and went through a decline of -4.82% in past 12-month trading. Industry’s another major player Amgen Inc (AMGN) has fell -0.13% down in previous session, but over the past year has faced a rise of 6.45%, while Gilead Sciences Inc (GILD) was also up 5.6% however its price remained floating in the red at 0% over the same period. AbCellera Biologics Inc. has a P/E ratio of 2827.78 against that of Bristol-Myers Squibb Company’s 0 while Amgen Inc is showing 20.32 for the same. On the other hand, the S&P 500 Index was up 0.03% in the last trading session while the Dow Jones Industrial closed the session lower at -0.04%.
Having a second look at AbCellera Biologics Inc. (NASDAQ:ABCL) provides that stock’s average daily trading volume for 3 months was 1.61 Million, while it dropped to 1.13 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 269.19 Million.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Even if you’re not actively in crypto, you deserve to know what’s actually going on…
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .